HALO
Halozyme Therapeutics Inc
NASDAQ: HALO · HEALTHCARE · BIOTECHNOLOGY
$63.06
-1.25% today
Updated 2026-04-29
Market cap
$7.47B
P/E ratio
24.63
P/S ratio
5.35x
EPS (TTM)
$2.56
Dividend yield
—
52W range
$48 – $82
Volume
1.6M
Halozyme Therapeutics Inc (HALO) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$63.06
12-Month target
$62.25
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.4B | $0.7B | $0.8B | $1.0B | $1.4B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 24.63x (capped 25x) · Margin: 22.70%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.